Healthcare
WuXi AppTec Co., Ltd.(WUXIF)
Live Price
Offline$16.01
-2.36% today
Window Change
-11.75%
Window
May 29, 2026 โ Jun 12, 2026
- Market Cap
- $270.95B
- Revenue Growth
- +15.8%
- EPS Growth
- +104.3%
- Dividend Yield
- 1.5%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 11 bars ยท May 29, 2026 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
WuXi AppTec Co., Ltd. (WUXIF) is a Healthcare stock with a market cap of $270.95B and listed on OTC. The stock last traded around $16.01 and down 11.8% across the available one-year price window (May 29, 2026 โ Jun 12, 2026). Baseline metrics include revenue growth of +15.8%, EPS growth of +104.3%, a dividend yield of 1.5%. What stands out right now is revenue +15.8%, EPS +104.3%, free cash flow +38.8% with operating margin 42.7% and ROIC 17.5%. The dividend is present but secondary, with a yield around 1.5%. Valuation is more restrained than many high-expectation growth names at P/E 15.9 and price/sales 5.6. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines WUXIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+15.8% vs +7.6% peer median
Operating Margin
Above sector median
+42.7% vs +19.4% peer median
P/E
Below sector median
15.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 27, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +15.8% and EPS at +104.3%, with operating margin around 42.7%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.5%, which matters if the thesis depends on income as much as growth.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WUXIF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
WUXIF Max Drawdown
-18.56%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for WUXIF and SPY.
Company Overview
WuXi AppTec Co., Ltd.
Other OTC
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
- Leadership
- Ge Li
- IPO Date
- Mar 17, 2020
- Employees
- 39.4k
- Street Address
- 288 Fute Zhong Road
- Mailing
- Shanghai, 200131
- Region
- Shanghai, CN
- Reporting Currency
- USD
- Investor Line
- 86 21 5046 1111
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 15.9
- EV/EBITDA
- 8.9
- Price/Sales
- 5.6
- Price/Book
- 3.8
Growth
- Revenue
- +15.8%
- EPS
- +104.3%
- Free Cash Flow
- +38.8%
Profitability
- Gross Margin
- 49.2%
- Operating Margin
- 42.7%
- Net Margin
- 41.7%
- ROE
- 27.3%
- ROIC
- 17.5%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 3.42
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.